SeekingAlpha · Aug 10, 2026
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet
Tyra Biosciences' dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. Read why TYRA stock is a Buy.
NASDAQ · TYRA
Tyra Biosciences, Inc.
Healthcare · Biotechnology
$25.69
Up+$0.36 (+1.40%)
Updated Aug 22, 2026, 1:35 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -12.83
- Dividend yield
- 0.00%
- 52-week range
- $11.70 – $40.65
- Volume
- 324.48K
- Avg. volume
- 330.86K
Price performance
TYRA price history
1M range · 20 trading sessions · Daily adjusted prices
TYRA closed at $25.69 after 20 trading sessions, down 16.13% for the selected period.
- Last close
- $25.69
- Period change
- -16.13%
- Period low
- $25.02
- Period high
- $33.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $26.36 | $26.36 | $25.0825 | $25.69 | 324.48K |
| Aug 19, 2026 | $26.69 | $26.98 | $26.27 | $26.81 | 303.63K |
| Aug 18, 2026 | $26.30 | $26.71 | $25.63 | $26.04 | 341.49K |
| Aug 17, 2026 | $25.00 | $27.055 | $24.98 | $26.22 | 596.34K |
| Aug 14, 2026 | $24.92 | $25.53 | $24.61 | $25.29 | 420.53K |
| Aug 13, 2026 | $25.33 | $25.45 | $24.83 | $25.02 | 528.38K |
| Aug 12, 2026 | $25.49 | $25.647 | $24.89 | $25.30 | 478.35K |
| Aug 11, 2026 | $26.25 | $26.445 | $24.75 | $25.18 | 730.13K |
| Aug 10, 2026 | $26.42 | $26.805 | $25.92 | $26.25 | 439.5K |
| Aug 7, 2026 | $27.38 | $27.82 | $26.1375 | $26.51 | 820.62K |
| Aug 6, 2026 | $25.69 | $27.33 | $25.68 | $26.96 | 776.09K |
| Aug 5, 2026 | $29.00 | $30.587 | $25.4625 | $25.71 | 2.74M |
| Aug 4, 2026 | $32.21 | $32.99 | $31.915 | $32.53 | 396.46K |
| Aug 3, 2026 | $31.06 | $32.56 | $30.82 | $32.04 | 507.32K |
| Jul 31, 2026 | $33.06 | $33.06 | $31.12 | $31.88 | 712.73K |
| Jul 30, 2026 | $31.39 | $33.26 | $31.0642 | $33.06 | 854.05K |
| Jul 29, 2026 | $31.32 | $31.80 | $30.16 | $31.11 | 496.08K |
| Jul 28, 2026 | $31.21 | $31.71 | $30.38 | $30.88 | 410.2K |
| Jul 27, 2026 | $30.79 | $32.26 | $30.79 | $31.06 | 473.79K |
| Jul 24, 2026 | $31.08 | $31.08 | $30.02 | $30.63 | 646.28K |
Latest TYRA news
The latest Smart Investors Daily articles mentioning TYRA.
Stock researchCompany · Overview
TYRA research
Overview
Company profile and research snapshot.
Company profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2026 | Jones Trading | Buy | — |
| Jun 10, 2026 | B of A Securities | Buy | — |
| May 19, 2026 | Wolfe Research | Peer Perform | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 15, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Tyra Biosciences Q2 EPS $(0.69) Misses $(0.65) Estimate
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.65) by 6.15 percent. This is a 46.81 percent decrease over losses of $(0.47) per share
Yahoo · Jun 23, 2026
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
Recently published Non-muscle Invasive Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-muscle invasive bladder cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Benzinga · Jun 10, 2026
Micron Technology To $900? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst ratings page for complete view.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
